Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
NCT01714817 · Bristol-Myers Squibb · PHASE3 · terminated · last registry update 2021-02-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Inability to meet protocol objectives.” | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD86 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-11-29Also stopped (terminated): Stuart Knechtle, M.D., Orencia® (Abatacept) (NCT04203875)
- 2021-11-02Results posted on the registry: Washington University School of Medicine, Belatacept + Tacrolimus (NCT03388008)
- 2021-09-23Also stopped (terminated): Ohio State University, Belatacept + Everolimus (NCT02134288)
- 2021-09-17Results posted on the registry: Bristol-Myers Squibb, Abatacept subcutaneous + Placebo (NCT02971683)
- 2021-09-08Results posted on the registry: Lorenzo Gallon, belatacept + Tacrolimus (NCT02213068)
- 2021-09-02Results posted on the registry: Massachusetts General Hospital, Belatacept + ATG (NCT02314403)
- 2021-08-24Results posted on the registry: Massachusetts General Hospital, Abatacept (NCT03669861)
- 2021-07-28Results posted on the registry: University of Cincinnati, Alemtuzumab + rabbit antithymocyte globulin (NCT01729494)
- 2021-06-22Results posted on the registry: Bristol-Myers Squibb, Thymoglobulin + Belatacept (NCT02137239)
- 2021-06-02Phase 3 first posted: Bristol-Myers Squibb, Abatacept + Adalimumab (NCT04909801)
- 2021-05-13Results posted on the registry: University of California, Los Angeles, abatacept also known as Orencia also known as CTLA4-Ig + Placebo (NCT02429934)
- 2021-05-13Also stopped (terminated): University of California, Los Angeles, abatacept also known as Orencia also known as CTLA4-Ig + Placebo (NCT02429934)
- 2021-05-07Phase 3 first posted: Bristol-Myers Squibb, Belatacept + Tacrolimus (NCT04877288)
- 2021-03-05Results posted on the registry: Bristol-Myers Squibb, Abatacept (NCT02592798)
- 2021-01-26Results posted on the registry: Andrew B Adams, Belatacept + Calcineurin inhibitor therapy (NCT01921218)
- 2021-01-07Results posted on the registry: Bristol-Myers Squibb, Abatacept (NCT03714022)
- 2021-01-05Results posted on the registry: Bristol-Myers Squibb, Belatacept + Tacrolimus (NCT01820572)
- 2020-12-31Phase 3 first posted: University of Alabama at Birmingham, targeted synthetic DMARD class + non-TNFi-biologic class (NCT04692493)
- 2020-12-01Also stopped (terminated): Medical University of Graz, bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept) (NCT01602302)
- 2020-11-25Results posted on the registry: Oklahoma Medical Research Foundation, Abatacept (NCT02270957)
- 2020-11-16Also stopped (withdrawn): University of California, Los Angeles, Abatacept + Placebo (NCT02053727)
- 2020-10-30Phase 3 first posted: University of Erlangen-Nürnberg Medical School, Prednisolone + Sulfasalazine (NCT04610476)
- 2020-10-20Phase 3 first posted: Daniel Benjamin, Infliximab + Abatacept (NCT04593940)
- 2020-10-01Results posted on the registry: Dr. Larry W. Moreland, TNF Antagonist (enbrel, humire, remicade, cimzia, symponi) + Abatacept (NCT02353780)
- 2020-10-01Also stopped (terminated): Dr. Larry W. Moreland, TNF Antagonist (enbrel, humire, remicade, cimzia, symponi) + Abatacept (NCT02353780)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision